We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




High Glucose Levels Predict Mortality in Pneumonia

By LabMedica International staff writers
Posted on 01 Oct 2012
Nondiabetic patients who have elevated serum glucose levels when they are admitted to the hospital with pneumonia have an increased risk of dying within 90 days. More...


Acute hyperglycemia associated with community-acquired pneumonia (CAP) can identify at-risk patients who need additional care to reduce their risk for mortality, compared with similar normoglycemic patients.

Scientists from the University Hospital of Saarland (Homburg, Germany) evaluated whether acute dysglycemia could predict a poor outcome in patients with CAP who had not been diagnosed with diabetes. They studied data from 6,891 adults with CAP who were enrolled in a prospective study from 2003 to 2009. The investigators also calculated various comorbidities for one month, three months and six months mortality on the basis of serum glucose levels at hospital admission. The majority of the patients were male, and the mean age was 60 years.

At the time of hospital admission, patients who had glucose levels from 6 to 11 mmol/L (108-198 mg/dL) were considered to have mild acute hyperglycemia and patients who had glucose levels of 14 mmol/L (252 mg/dL) or more were considered to have acute hyperglycemia. In all, 40% of CAP patients presented with hyperglycemia. An elevated glucose level at hospital admission was an independent predictor of one month, three months and six months mortality in CAP patients. In fact, increasing glucose levels corresponded to increasing risk for death from CAP.

Patients with mild to moderate hyperglycemia had a significantly higher hazard ratio (HR) for mortality at 90 days than patients with normal glucose levels at hospital admission. In patients presenting with acute hyperglycemia, HR increased to 6.04. In patients previously diagnosed with diabetes, there was no association between glucose level at admission and mortality. However, there was a nearly two-fold increased risk of dying in the 16% of patients with preexisting diabetes.

Philipp M. Lepper, MD, the senior investigator, said, "Increased serum glucose levels at admission are a risk factor for death among patients with community-acquired pneumonia. The risk for mortality starts to increase when serum glucose levels are slightly increased but remain below the defined threshold for overt diabetes." The study was presented on September 2, 2012, at the European Respiratory Society (ERS) 2012 Annual Congress held in Vienna Austria.

Related Links:

University Hospital of Saarland




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.